ESTABLISHING AN IN-SILICO MEDICATION TOWARDS TREATMENT OF PETIT MAL EPILEPSY

Pal A.¹*, Behera J.², Sahoo J.³, Swain T.⁴, Sahu P.K.^5
1School of Pharmaceutical Sciences, Siksha O Anusandhan University, Bhubaneswar, India
²School of Pharmaceutical Sciences, Siksha O Anusandhan University, Bhubaneswar, India
³School of Pharmaceutical Sciences, Siksha O Anusandhan University, Bhubaneswar, India
⁴School of Pharmaceutical Sciences, Siksha O Anusandhan University, Bhubaneswar, India
⁵School of Pharmaceutical Sciences, Siksha O Anusandhan University, Bhubaneswar, India
* Corresponding Author : abhipharma_2000@yahoo.co.in

Received : -     Accepted : -     Published : 21-12-2010
Volume : 2     Issue : 2       Pages : 1 - 4
Int J Pharmaceut Anal 2.2 (2010):1-4
DOI : http://dx.doi.org/10.9735/0975-3079.2.2.1-4

Keywords : Docking, HEX, Ethosuximide, Lipinski, Petitmal
Conflict of Interest : None declared

Epilepsy is a neurological disorder. About 0.5%-1% of world population is affected by epilepsy. Petit mal epilepsy is the main seizure type in 15-20% of epileptic children. The mainstream intervention for petit mal epilepsy is T-type Ca ++ channel blocker like ethosuximide. However, there is a need for safer and effective drug. The protein-ligand interaction plays a significant role in structure based drug designing. In the present work we have taken t-type calcium channel as the target and identified natural compounds that can be used against petit mal epilepsy. Here the drug ethosuximide is used as standard (E value = -132.35). Twelve natural compounds are retrieved from PubMed and are checked for drug likeness with bioinformatics tool ADMETox to satisfy Lipinski’s rule of five. Ten natural drugs qualify this step and are docked with receptor using HEX docking software. All the compounds taken for docking were found to be better than the conventional drug, Ethosuximide.

[1] Rang H.P., Dale M.M., Ritter J.M., and Flower R.J. (2007) Antiepileptic drugs. In: Pharmacology, 6th edition, Churchill Livingstone Elsevier, China, 575-87  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus  

[2] Sylvin M. (2009) Drug Design, 1st edition, Sarup Book Publishers Pvt Ltd, New Delhi, 6-11  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus  

[3] Alberto A. and Diego B. (2006) Current Bioinformatics, 1, 3-13  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus  

[4] David W. R. (2002) Proteins, Structure, Function and Genetics, Wiley-Liss Inc., 1-22  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus  

[5] Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N. and Bourne P.E. (2000) Nucleic Acids Research, 28 (1), 235- 242  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus  

[6] Sharma H.L., Sharma K.K. (2007) Principles of Pharmacology, 1st edition, Paras Publishing, Delhi, 529-543  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus  

[7] Ganguly S., Mazumder M., Basu P., Roy P., Mitra S. and Datta A. (2010) BMC Bioinformatics, 11 (Suppl1), S13  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus  

[8] Virupakshaiah D.B.M., Kelmani C., Patil R. and Hegade P. (2007) World Academy of Science, Engineering and Technology, 30, 297-299.  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus  

[9] Verlinde C.L.and Hol W.G. (1994) Structure, 2 (7), 577–87  
» CrossRef   » Google Scholar   » PubMed   » DOAJ   » CAS   » Scopus